BR112014032987A2 - método de tratamento ou profilaxia de um distúrbio neurológico - Google Patents
método de tratamento ou profilaxia de um distúrbio neurológicoInfo
- Publication number
- BR112014032987A2 BR112014032987A2 BR112014032987A BR112014032987A BR112014032987A2 BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2 BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2
- Authority
- BR
- Brazil
- Prior art keywords
- prophylaxis
- treatment
- neurological disorder
- œmethod
- ago
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668134P | 2012-07-05 | 2012-07-05 | |
| PCT/EP2013/064063 WO2014006105A1 (en) | 2012-07-05 | 2013-07-03 | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014032987A2 true BR112014032987A2 (pt) | 2017-06-27 |
Family
ID=48741180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014032987A BR112014032987A2 (pt) | 2012-07-05 | 2013-07-03 | método de tratamento ou profilaxia de um distúrbio neurológico |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102279751B1 (ko) * | 2019-06-28 | 2021-07-21 | 경북대학교 산학협력단 | 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법 |
| KR102409771B1 (ko) * | 2020-06-17 | 2022-06-16 | 경북대학교 산학협력단 | Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| DE10336350B4 (de) | 2003-08-08 | 2007-10-31 | Westfalia Separator Ag | Vollmantel-Schneckenzentrifuge, mit Schälscheibe |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| RU2362780C2 (ru) | 2003-12-22 | 2009-07-27 | Глаксо Груп Лимитед | Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| PL2207808T3 (pl) | 2007-11-02 | 2013-11-29 | Novartis Ag | Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne |
| US20110268729A1 (en) | 2008-07-11 | 2011-11-03 | Bams Abila | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
-
2013
- 2013-07-03 RU RU2014150265A patent/RU2014150265A/ru not_active Application Discontinuation
- 2013-07-03 KR KR20157003097A patent/KR20150036398A/ko not_active Withdrawn
- 2013-07-03 CA CA2876284A patent/CA2876284A1/en not_active Abandoned
- 2013-07-03 EP EP13732986.8A patent/EP2870177A1/en not_active Withdrawn
- 2013-07-03 AU AU2013285493A patent/AU2013285493A1/en not_active Abandoned
- 2013-07-03 BR BR112014032987A patent/BR112014032987A2/pt not_active IP Right Cessation
- 2013-07-03 CN CN201380035806.8A patent/CN104395343A/zh active Pending
- 2013-07-03 WO PCT/EP2013/064063 patent/WO2014006105A1/en active Application Filing
- 2013-07-03 IN IN2952KON2014 patent/IN2014KN02952A/en unknown
- 2013-07-03 JP JP2015519214A patent/JP2015521992A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014150265A (ru) | 2016-08-27 |
| WO2014006105A1 (en) | 2014-01-09 |
| EP2870177A1 (en) | 2015-05-13 |
| KR20150036398A (ko) | 2015-04-07 |
| CN104395343A (zh) | 2015-03-04 |
| CA2876284A1 (en) | 2014-01-09 |
| IN2014KN02952A (enrdf_load_html_response) | 2015-05-08 |
| JP2015521992A (ja) | 2015-08-03 |
| AU2013285493A1 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394273B (es) | Lipido que comprende acido docosapentaenoico. | |
| SG10201903962PA (en) | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme | |
| MX2017012421A (es) | Modulo de elemento de calentamiento para un dispositivo generador de aerosol. | |
| TR201811764T4 (tr) | Kinaz inhibitörleri olarak aminoheteroaril benzamidleri. | |
| MX2014010481A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| BR112015024674A2 (pt) | método para aumentar a capacidade de sobrevivência de um ou mais microrganismos benéficos e para revestir uma semente, e, composição | |
| MX2015012401A (es) | Composiciones y metodos de alterar niveles de colesterol. | |
| PH12016501160A1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| BR112016012840A2 (pt) | Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre | |
| BR112013000768A2 (pt) | asparaginase de basidiomicetos | |
| MX376793B (es) | Preparaciones de éster de ácido fosfórico con higroscopia reducida. | |
| MX2015010077A (es) | Terapia de combinacion para el tratamiento de neumonia nosocomial. | |
| EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
| PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
| BR112015031541A2 (pt) | métodos para o impedimento da agregação de componentes virais | |
| HK1223632A1 (zh) | 靶向的酶化合物及其用途 | |
| UY32075A (es) | Estabilización de preparaciones acuosas de minerales mediante reuterina | |
| MX2015006616A (es) | Doble direccion. | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| BR112014032987A2 (pt) | método de tratamento ou profilaxia de um distúrbio neurológico | |
| JOP20140008B1 (ar) | استخدام العوامل المساعدة لمستقبل ألفا 7 أسيتيل كولين نيكوتينية | |
| MX338405B (es) | Formulaciones de 2-iminobiotina y sus usos. | |
| CL2015002069A1 (es) | Métodos para el uso de compuestos de fenoxipropilamina para tratar la depresión. | |
| MX2013000539A (es) | Nuevas formulaciones de analogos 14-epi de la vitamina d. | |
| EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |